Table 3.
Psychiatric adverse events in oseltamivir prophylaxis trials
| Event type | No of events* (%) | ||
|---|---|---|---|
| Oseltamivir (n=2000) | Placebo (n=1434) | Total (n=3434) | |
| Confusion | 5 (0.25) | 1 (0.07) | 6 (0.17) |
| Depression | 14 (0.7) | 6 (0.42) | 20 (0.58) |
| Hallucinations | 2 (0.1) | 0 (0.00) | 2 (0.06) |
| Anxiety | 7 (0.35) | 8 (0.56) | 15 (0.44) |
| Psychosis | 2 (0.1) | 1 (0.07) | 3 (0.09) |
| Schizophrenia | 1 (0.05) | 0 (0.00) | 1 (0.03) |
| Bipolar disorder | 0 (0) | 1 (0.07) | 1 (0.03) |
| Sleeping disorder | 2 (0.1) | 0 (0.00) | 2 (0.06) |
| Aggression | 1 (0.05) | 0 (0.00) | 1 (0.03) |
| Stress symptoms | 3 (0.15) | 0 (0.00) | 3 (0.09) |
| Restlessness | 1 (0.05) | 0 (0.00) | 1 (0.03) |
| Nervousness | 1 (0.05) | 0 (0.00) | 1 (0.03) |
| Suicide ideation | 1 (0.05) | 0 (0.00) | 1 (0.03) |
| Paranoia | 1 (0.05) | 0 (0.00) | 1 (0.03) |
| Alcohol related | 6 (0.3) | 2 (0.14) | 8 (0.23) |
| Total | 47 (2.35) | 19 (1.32) | 66 (1.92) |
*47 events occurred in 44 patients in the oseltamivir arms.